Le Lézard
Classified in: Health, Science and technology
Subjects: FDA, PET, ANW

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites


DULUTH, Ga., July 20, 2023 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved the newest innovation from the trusted NexGard® Brand of Products ? NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets) ? a monthly beef-flavored soft chew that protects dogs from fleas, ticks, heartworm disease, roundworms and hookworms. By combining internal and external parasite protection in a tasty, beef-flavored soft chew, NexGard® PLUS helps make monthly compliance easy and enjoyable for pets and pet owners.

"We're committed to making it as easy as possible to care for pets, and NexGard® PLUS builds on our legacy in pet health to bring one-and-done monthly parasite protection to dogs in a beef-flavored soft chew," said Daniel Watkins, Vice President of U.S. Pet at Boehringer Ingelheim Animal Health.  

With NexGard® PLUS, Boehringer Ingelheim adds to its robust parasiticide portfolio, giving veterinarians the flexibility to prescribe the right products for each pet and pet owner's needs, including:

Safe and effective against growing parasite threats

Internal and external parasite threats have expanded beyond their traditional regions and seasons.  Many tick species, for example, are now found in places that they didn't exist a decade ago, and they are searching for a host whenever temperatures are above freezing. Fleas can be an ever-present risk for dogs throughout the U.S., and the heartworm disease prevalence has increased across much of the country. This is a contributing factor in the Companion Animal Parasite Council (CAPC) recommending that pet owners administer year-round broad-spectrum parasite control with efficacy against heartworm, intestinal parasites, fleas, and ticks.4

Multiple clinical studies showed that NexGard® PLUS is safe and effective against these growing threats: 4,5

Advancing Pet Healthcare Through Innovation

Each NexGard® PLUS chew has the same proven afoxolaner dose prescribed to millions of dogs in NexGard® (afoxolaner),6 and an optimized dose of moxidectin that is proven safe and effective.

To further enable compliance, veterinarians can prescribe 3-dose and 6-dose presentations to best support the needs of their canine patients.

"NexGard® PLUS is the one veterinarians will want to help keep dogs protected from parasites. It offers internal and external parasite protection in a single monthly chew that dogs will enjoy, is backed by our clinic support team, and is the latest innovation in our trusted parasiticide portfolio," said Whit Cothern, DVM, Executive Director of Veterinary Professional Services at Boehringer Ingelheim Animal Health. "Veterinarians tackle complex challenges in their clinics every day, so we are proud to offer the solutions you want and the customer care that you want ? all in one place."

NexGard® PLUS will be available for veterinary clinics to order on July 31.

NexGard® PLUS Important Safety Information

NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only. The most frequently reported adverse reactions reported in clinical trials were diarrhea, vomiting, lethargy, and itching. NexGard® PLUS contains afoxolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of NexGard® PLUS has not been evaluated in breeding, pregnant, or lactating dogs. Dogs should be tested for existing heartworm infection prior to starting a heartworm disease preventive. For more information, click here for full prescribing information, or visit NexGardPLUSClinic.com.

NexGard® COMBO Important Safety Information

NexGard® COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution) is for topical use only in cats. Use with caution in cats with a history of seizures or neurologic disorders. For more information, click here for full prescribing information or visit NexGardCOMBOClinic.com.

NexGard® Important Safety Information

NexGard® (afoxolaner) is for use in dogs only. The most frequently reported adverse reactions include vomiting, pruritus, lethargy, diarrhea, and lack of appetite. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures or neurologic disorders. For more information, click here for full prescribing information or visit NexGardClinic.com.

HEARTGARD® Plus Important Safety Information

HEARTGARD® Plus (ivermectin/pyrantel) is for dogs only. All dogs should be tested for heartworm infection before starting a preventive program. Following the use of HEARTGARD Plus, digestive and neurologic side effects have been reported. For more information, click here for full prescribing information.

Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.

For more information visit www.boehringer-ingelheim.com/animal-health.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Animal Health Headquarters in Duluth, Georgia, and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contact:

Brett Israel
Boehringer Ingelheim Animal Health
Director of PR and Communications, U.S. Pets
[email protected]

1 Data on file at Boehringer Ingelheim.

2 Data on file at Boehringer Ingelheim.

3 Data on file at Boehringer Ingelheim.

4 Guidelines for Dogs and Cats, Companion Animal Parasite Council. https://capcvet.org/guidelines/general-guidelines/

5 Freedom of Information Summary, NADA 141-554. NexGard PLUS (afoxolaner, moxidectin, and pyrantel chews)

6 Data on file at Boehringer Ingelheim.

NexGard® is a registered trademark and NexGard COMBOtm is a trademark of Boehringer Ingelheim Animal Health France, used under license. HEARTGARD® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0590-2023

SOURCE Boehringer Ingelheim


These press releases may also interest you

at 03:00
The New Norm A Media Snippet accompanying this announcement is available by clicking on this link. Globally, 4 out of 5 people who need hearing aids don't wear them, leaving an estimated 344 million people missing out on the sounds of life,...

2 mar 2024
Inc. Magazine revealed that GetMed Staffing is No. 23 on its fourth annual Inc. Regionals: Midwest list, the most prestigious ranking of the fastest-growing Midwest private...

2 mar 2024
With Super Tuesday around the corner and the next presidential election looming, many of us are feeling our anxiety rise. If you've found yourself tossing and turning at night, unable to relax the tension in your shoulders, or even having stomach...

2 mar 2024
Scarborough Health Network (SHN) Foundation is thrilled to announce a generous donation of $1 million from the Honey & Barry Sherman Legacy Foundation to support exceptional healthcare for Scarborough. $1 million to Scarborough Health Network from...

1 mar 2024
The deadline for the Registered Nurses' Association of Ontario's (RNAO) annual Media Awards competition has been extended until March 8. The competition honours outstanding nursing and health-care journalism in a variety of categories: community...

1 mar 2024
On Thursday, February 29, an Allegheny County jury awarded a 62-year-old man from Mars, PA, $1.4 million in damages for negligence resulting from a fall that caused permanent injury to his dominant arm. The incident occurred when the man was admitted...



News published on and distributed by: